Abnormal overexpression of EVI1 and, therefore, activation of its underlying transcriptional program, are involved in up to a quarter of pediatric acute myeloid leukemia (AML), and influence prognosis and response to chemotherapy in this setting [3,4]. This evidence concerns the gene MECOM and acute myeloid leukemia.